Lysophosphatidic Acid Receptor Subtype-1 Antagonist PIPE-791 Reduces Neuropathic Pain in Macaques

/in , /by

Aldric Hama, Karin Stebbins, Chris Baccei, Daniel Lorrain, Austin Chen, Takahiro Natsume, Hiroryuki Takamatsu

Presented at IASP 2024 World Congress on Pain

Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis

/in , /by

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana J. Lorenzana, Jeffrey R. Roppe, Jill M. Baccei, Christopher S. Baccei, Austin C. Chen, Ari J. Green, Daniel S. Lorrain, and Jonah R. Chan

PNAS

Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis

/in , /by

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana O. Lorenzana, Bryanna E. Paulson, Christopher S. Baccei, Jeffrey R. Roppe, Thomas O. Schrader, Lino J. Valdez, Yifeng Xiong, Austin C. Chen & Daniel S. Lorrain

Scientific Reports

Active MS lesions are characterized by high LPA1 expression and PIPE-791 promotes remyelination via LPA1 inhibition in the cuprizone model

/in , /by

Didier Bagnol, Alexander R Broadhead, Geraldine C Edu, John Atkins, Christopher S Baccei, Kym I Lorrain, Michael M Poon, Jeffrey R Roppe, Thomas O Schrader, Lino J Valdez, Yifeng Xiong, Austin C Chen, Daniel S Lorrain

Presented at Gordon Research Conference (GRC) 2024

©2025 Contineum Therapeutics Terms of Use Privacy Policy Linkedin Linkedin